Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 23, 2026Open Access

Hepatology: Emerging Paradigms in MASLD, Viral Hepatitis, Cholestatic Liver Disease, Portal Hypertension and Hepatocellular Carcinoma: Summary of the First Annual Paris International Liver Meeting 2026.

View Full Paper
Ask AI
Bookmark
Share

Authors

ZYZobair M YounossiGPGeorge PapatheodoridisETEmmanuel Tsochatzis

Discussion

Loading...

Member takes

Overview

Conference review highlights precision therapeutics and non-invasive testing in chronic liver disease, signaling a transition toward mechanism-driven early interventions.

Key Points

  • To summarize transformative diagnostic, prognostic, and therapeutic breakthroughs across chronic liver diseases presented at the First Annual Paris International Liver Meeting 2026.
  • Synthesized expert consensus and clinical evidence covering metabolic dysfunction-associated steatotic liver disease (MASLD), viral hepatitis (HBV/HDV), cholestatic conditions (PBC/PSC), portal hypertension, and hepatocellular carcinoma.
  • Established resmetirom and semaglutide as approved disease-modifying therapies for MASH with F2-F3 fibrosis, supported by a pipeline of FGF21 analogs and incretin agonists demonstrating strong anti-fibrotic activity.
  • Identified functional cure strategies for HBV and HDV via simplified algorithms, bulevirtide, and RNA-silencing therapies, alongside novel PPAR agonists improving cholestasis and pruritus in PBC.
  • Demonstrated expanded utility of non-invasive tests for risk stratification and highlighted immunotherapy combinations delivering unprecedented survival gains in hepatocellular carcinoma.

Cite This Study

Younossi et al. (2026) studied this question.

synapsesocial.com/papers/6a8aadd57677a3411444638dhttps://doi.org/10.48620/100386
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Upcoming therapies for steatotic liver disease: Translating breakthroughs into clinical practice2026
  2. 2A new era in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): clinical breakthroughs and challenges2026
  3. 3Advances in Diagnostic and Therapeutic Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease2026
  4. 4The Evolution of MASLD Management: From Revised Nomenclature to Disease-Modifying Therapies2026
  5. 5Therapeutic Landscape Evolution: From Lifestyle Interventions to Precision Pharmacotherapy2026